Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Remigio Civitarese
Aprile 20, 2017

Arena Pharmaceuticals, a biopharmaceutical company. (ARNA) is at 34.24. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment. While the company's share hit the 52 week high on 04/20/16 stationing the value of $2.80. Price Target plays a critical role when it comes to the analysis of a Stock.

The objective of a stock price analysis is to study the behaviour of stock prices.

Arena Pharmaceuticals, Inc. has a consensus hold rating from 6 Wall Street analysts, and the number of shares now sold short amount to at least 3.64% of shares outstanding. EPS breaks down the profitability of the company on a single share basis. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. A "Buy" rating does not mean that every investor should acquire the stock. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.

Currently, EPS of Amedica Corporation (AMDA) is -0.3 while the analysts predicted the EPS of the stock to be -0.15 suggesting the company fell short of the analysts' expectations.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) tumbled -9.86% year-to-date. It is the "top line" or "gross income" figure from which costs are subtracted to determine net income.

The company's expected revenue in the current quarter to be 8.07 Million, seeing a projected current quarter growth of 22.2%, and per annum growth estimates over the next 5 year period of around -20.2%. The Higher end of the revenue forecast is $24.35 Million, while the Lower end of the forecast is $3.1 Million. Arena Pharmaceuticals's revenue for the quarter was up 994.9% compared to the same quarter a year ago.

A moving average (MA) is a trend-following or lagging indicator because it is based on past prices.

It is important to consider the moving averages of a downtrending security. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range. (ARNA)'s latest closing price distance was at -17.84% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -13.54% and -11.43% compared with the 20 Day Moving Average. The 1-year High price of the stock is $2.16, while the 1-year low price is $1.34. Over the 52-week time span, the stock notched a high price of $2.16 and its minimum price was $1.2.

03/06/2015 - Arena Pharmaceuticals, Inc. was downgraded to "underperform" by analysts at Zacks. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

Separately, TheStreet raised Juniper Pharmaceuticals from a "d+" rating to a "c" rating in a research note on Wednesday, April 12th. ARNA's value Change from Open was at 4.07% with a Gap of -16.89%. The research firm Initiated the stock to Outperform. WallachBeth also Initiated the company to Buy on 15-Nov-13, 2016. Examples of analysis performed within this article are only examples.

Arena Pharmaceuticals, Inc.'s RSI is 33.36. The stock climbed 4.23 percent over the past quarter, while declined -12.43 percent over the past six months.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE